Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
gene therapy |
gptkbp:administeredBy |
gptkb:physician
|
gptkbp:approvalYear |
2020-07-24
|
gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
gptkbp:ATCCode |
L01XL10
|
gptkbp:blackBoxWarning |
yes
|
gptkbp:developedBy |
gptkb:Kite_Pharma
|
gptkbp:genericName |
gptkb:brexucabtagene_autoleucel
|
https://www.w3.org/2000/01/rdf-schema#label |
Tecartus
|
gptkbp:indication |
gptkb:mantle_cell_lymphoma
leukemia |
gptkbp:legalStatus |
prescription only
|
gptkbp:marketedAs |
gptkb:Gilead_Sciences
|
gptkbp:mechanismOfAction |
CD19-directed genetically modified autologous T cell immunotherapy
|
gptkbp:pregnancyCategory |
not recommended
|
gptkbp:routeOfAdministration |
intravenous
|
gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
gptkbp:storage |
cryopreserved
|
gptkbp:bfsParent |
gptkb:gene_therapy
|
gptkbp:bfsLayer |
5
|